VIVUS (VVUS) Qsymia Sales Lag Investor Sentiment in Nov.; Many Expect Better FY13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Nike out of World Cup contention as Adidas-outfitted teams head to final
Vivus (VVUS) Surges as Qsymia Prescriptions Rise 46%
December 17, 2012 9:46 AM ESTVivus, Inc. (NASDAQ:... More
VIVUS (VVUS) Qsymia Prescriptions Pop Following Thanksgiving Glut (ARNA) (OREX)
December 10, 2012 9:10 AM ESTVIVUS, Inc. (Nasdaq: VVUS) is ticking higher in early trading Monday following reports that Qsymia prescriptions rose following the Thanksgiving holiday.... More
